Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin

Clinical Toxicology

Volumn 50, Issue 10, 2012, Pages 896-901

  Yook, Ji Hyoung ^a   Han, Jung Yeol ^b   Choi, June Seek ^b   Ahn, Hyun Kyoung ^b   Lee, Si Won ^b   Kim, Moon Young ^b   Ryu, Hyun Mee ^b   Nava Ocampo, Alejandro A ^c,d,e  

^a Seoul Medical Center   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c PharmaReasons Pharmacological Research and Applied Solutions   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Congenital abnormalities; Prenatal care; Retinoids; Teratogens

Indexed keywords

ISOTRETINOIN;

ACNE; ADULT; ARTICLE; CONCEPTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; SELF REPORT; SPONTANEOUS ABORTION;

ABNORMALITIES, DRUG-INDUCED; ABORTION, EUGENIC; ACNE VULGARIS; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; ISOTRETINOIN; LIVE BIRTH; PREGNANCY; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TERATOGENS;

EID: 84871865363     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2012.739287     Document Type: Article

References (22)

1. Tang GW, Russell RM. 13-cis-retinoic acid is an endogenous compound in human serum. J Lipid Res 1990; 31: 175-182.
2. Lowenstein EB, Lowenstein EJ. Isotretinoin systemic therapy and the shadow cast upon dermatology ' s downtrodden hero. Clin Dermatol 2011; 29: 652-661.
3. Rosa FW. Teratogenicity of isotretinoin (letter). Lancet 1983; 2: 513.
4. Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. Teratology 1986; 33: 355-364.
5. Nau H. Teratogenicity of isotretinoin revisited: species variation and the role of all-trans-retinoic acid. J Am Acad Dermatol 2001; 45. S183 - S187.
6. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
7. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a populationbased perspective. Br J Clin Pharmacol 2007; 63: 196-205.
8. Garcia-Bournissen F, Tsur L, Goldstein LH, Staroselsky A, Avner M, Asrar F, et al. Fetal exposure to isotretinoin - an international problem. Reprod Toxicol 2008; 25: 124-128.
9. Autret-Leca E, Kreft-Jais C, Elefant E, Cissoko H, Darrouzain F, Grimaldi-Bensouda L, et al. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Drug Saf 2010; 33: 659-665.
10. Schaefer C, Meister R, Weber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 2010; 281: 221-227.
11. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-841.
12. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26: 599-606.
13. United Kingdom Teratology Information Service (UKTIS). U se of isotretinoin in pregnancy. 2008. Available at http://www.uktis.org./index.html. Accessed August 7, 2012.
14. Grønhøj LF, Jakobsen P, Grønhøj LC, Heidenheim M, Held E, Nielsen-Kudsk F. The metabolism and pharmacokinetics of isotretinoin in patients with acne and rosacea are not influenced by ethanol. Br J Dermatol 2009; 161: 664-670.
15. Wyss R, Bucheli F. Determination of endogenous levels of 13. cis-retinoic acid (isotretinoin), all-trans-retinoic acid (tretinoin) and their 4-oxo metabolites in human and animal plasma by high-performance liquid chromatography with automated column switching and ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997; 700: 31-47.
16. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006; 3. e483.
17. Han JY, Nava-Ocampo AA, Koren G. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Res A Clin Mol Teratol 2005; 73: 245-248.
18. Lee SW, Han JY, Choi JS, Chung JH, Kim MY, Yang JH, et al. Pregnancy outcome of women inadvertently exposed to ribostamycin during early pregnancy: a prospective cohort study. Reprod Toxicol 2009; 27: 196-198.
19. Lee HJ, Han JY, Yook JH, Choi JS, Ahn HK, Kim MY, et al. A prospective cohort study of pregnancy outcomes of women inadvertently exposed to methylephedrine in the 1st trimester of pregnancy. J Obstet Gynaecol 2010; 30: 563-566.
20. Lee JE, Han JY, Choi JS, Ahn HK, Lee SW, Kim MH, et al. Pregnancy outcome after exposure to the probiotic Lactobacillus in early pregnancy. J Obstet Gynaecol 2012; 32: 227-229.
21. Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol 2011; 25: 1094-1098.
22. Helbig A, Kaasen A, Malt UF, Haugen G. Psychological distress after recent detection of fetal malformation: short-term effect on second-trimester uteroplacental and fetoplacental circulation. BJOG 2011; 118: 1653-1657.